Conditions: Recurrent Hepatitis C
Keywords: Fibrosis progression recurrent hepatitis C viral infection liver transplant recipients everolimus Hepatitis C recurrence after orthotopic liver transplantation (OLT)
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 43
Healthy volunteers: no

Brief summary:
This study will assess the efficacy of everolimus as an inhibitor of fibrosis progression in liver transplant patients who have a recurrence of hepatitis C viral infection in the transplant

Detailed description:

Arms:
arm 1: Continuation of current immunosuppressive regimen (continuation of Calcineurin Inhibitor \[CNI\] with or without Enteric-coated mycophenolate sodium (myfortic) or mycophenolate mofetil(Cellcept)\[MPA\], with or without steroids) / no everolimus introduction. arm 2: Initiation of everolimus with discontinuation of CNI/MPA, with or without steroids.

Interventions: intervention 1: CsA-TAC (standard Treatment) intervention 2: Everolimus
Intervention descriptions: intervention 1: Continuation of current immunosuppressive regimen (continuation of CNI with or without MPA, with or without steroids) / no everolimus introduction. intervention 2: Hepatitis C recurrence after orthotopic liver transplantation (OLT)

Protocol document: